All‐cause short‐term mortality: 1 month · adults with low cardiac output syndrome
It is very uncertain whether enoximone changes all‐cause short‐term mortality: 1 month compared with dobutamine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality: 60 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause long‐term mortality: 60 days compared with norepinephrine (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality: range 4 to 12 months · people with cardiogenic shock or low cardiac output syndrome
Levosimendan showed no clear difference in all‐cause long‐term mortality: range 4 to 12 months compared with dobutamine (low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 1 month · adults with cardiogenic shock or low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome
It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 30 days · adults with cardiogenic shock
It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine‐dobutamine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: time in hospital · adults with low cardiac output syndrome
It is very uncertain whether dopexamine changes all‐cause short‐term mortality: time in hospital compared with dopamine (very low certainty).
1 finding from 1 review
Intervention not reported
PIPP score (difference between baseline and heel lance period) · Neonates
1 finding from 1 review
Intervention not reported
Duration of crying (seconds) during the first 3 minutes · Neonates
1 finding from 1 review
Intervention not reported
PIPP (maximum score within 3 minutes following lancing) · Neonates
1 finding from 1 review
Intervention not reported
PIPP score in first 45 seconds of eye examination · Neonates
1 finding from 1 review
Intervention not reported
PIPP score 5 minutes after eye examination · Neonates
1 finding from 1 review
Intervention not reported
Lung function Mean percentage change in FEV1 · adults and children with cystic fibrosis
1 finding from 1 review